Brought to you by 
Janssen gets rights to Achillion's HCV assets; deal terminated
May 2015
Executive Summary
Achillion Pharmaceuticals Inc. licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize hepatitis C compounds including ACH3102, ACH3422, and sovaprevir (ACH1625).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen gets rights to Achillion's HCV assets; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice